Experimental antiviral drug with potential activity against RNA viruses.
1 In contrast, T-705 acts as a potent and GTP-competitive inhibitor of the viral polymerase.
2 T-705 (favipiravir) is a new antiviral agent in advanced clinical development for influenza therapy.
3 Influenza virus-infected cell cultures were exposed to T-705 or ribavirin during single or serial virus passaging.
4 This mutagenic effect is 2-fold higher for T-705 than for ribavirin.
5 Whereas neuraminidase inhibitors slow down viral replication, T-705 is a viral RNA polymerase inhibitor which prevents viral replication.
6 These mechanisms were also proposed for ribavirin, an established and broad antiviral drug that shares structural similarity with T-705.
7 We here performed a comparative analysis of the effects of T-705 and ribavirin on influenza virus and host cell functions.
8 T-705 is also currently in phase I trials in Japan where it has been put on the Health Ministry's priority list for development.
9 Survival and virological characteristics were observed for 85 patients in the control group and 39 in the T-705 treatment group.
Grammar, pronunciation and more